Loss of heterozygosity of 14q32 in colorectal carcinoma
- PMID: 10347556
- DOI: 10.1016/s0165-4608(98)00242-8
Loss of heterozygosity of 14q32 in colorectal carcinoma
Abstract
Previous allelotyping studies on colorectal carcinoma suggest that loss of heterozygosity (LOH) on chromosome 14q may be a common genetic alteration in this tumor type. The purpose of this study was to determine precise frequency of LOH at 14q32 region in colorectal carcinomas and to define a minimal region of LOH. LOH at 14q32 in 66 primary colorectal carcinomas were analyzed by polymerase chain reaction-based deletion mapping using six highly polymorphic microsatellites. The average rate of informative data was 68.2% in all cases of colorectal carcinoma analyzed. The average rate of LOH at 14q32 was 44.1%, with the highest frequency of 50.0% at D14S267 locus in the informative cases. The minimal region of LOH was defined by markers D14S65 and D14S250 at 14q32. The present data provide useful information for the isolation of tumor suppressor genes from this region.
Similar articles
-
Allelic imbalance of 14q32 in esophageal carcinoma.Cancer Genet Cytogenet. 2002 Jun;135(2):177-81. doi: 10.1016/s0165-4608(01)00654-9. Cancer Genet Cytogenet. 2002. PMID: 12127403
-
Metastatic recurrence of early-stage colorectal cancer is linked to loss of heterozygosity on chromosomes 4 and 14q.J Clin Pathol. 2006 Jun;59(6):624-30. doi: 10.1136/jcp.2005.033167. J Clin Pathol. 2006. PMID: 16731603 Free PMC article.
-
Chromosome 14q may harbor multiple tumor suppressor genes in primary glioblastoma multiforme.Chin Med J (Engl). 2002 Aug;115(8):1201-4. Chin Med J (Engl). 2002. PMID: 12215292
-
Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.Adv Exp Med Biol. 1997;407:41-53. doi: 10.1007/978-1-4899-1813-0_7. Adv Exp Med Biol. 1997. PMID: 9321930 Review.
-
[Genetic backgrounds in superficial- and superficial depressed-type colorectal cancer].Nihon Shokakibyo Gakkai Zasshi. 2002 May;99(5):469-73. Nihon Shokakibyo Gakkai Zasshi. 2002. PMID: 12048889 Review. Japanese. No abstract available.
Cited by
-
The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms.Front Pharmacol. 2023 Apr 19;14:1152672. doi: 10.3389/fphar.2023.1152672. eCollection 2023. Front Pharmacol. 2023. PMID: 37153758 Free PMC article. Review.
-
A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers.PLoS Biol. 2020 Mar 23;18(3):e3000666. doi: 10.1371/journal.pbio.3000666. eCollection 2020 Mar. PLoS Biol. 2020. PMID: 32203529 Free PMC article.
-
Associations between polymorphisms of long non-coding RNA MEG3 and risk of colorectal cancer in Chinese.Oncotarget. 2016 Apr 5;7(14):19054-9. doi: 10.18632/oncotarget.7764. Oncotarget. 2016. PMID: 26934323 Free PMC article.
-
DICER1 and PRKRA in Colon Adenocarcinoma.Biomark Insights. 2008 Apr 28;3:253-258. doi: 10.4137/bmi.s600. Biomark Insights. 2008. PMID: 19578509 Free PMC article.
-
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.Oncotarget. 2015 Oct 20;6(32):32774-89. doi: 10.18632/oncotarget.5192. Oncotarget. 2015. PMID: 26416415 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical